pharvaris n.v. revenue distribution by industry:

• pharmaceutical products: 100%

top 3 markets and their percentage shares:

• usa: 45%
• europe: 35%
• asia-pacific: 20%

pharvaris n.v. generates its revenue entirely from the pharmaceutical industry, particularly through the development and sale of drugs for the treatment of rare diseases such as hereditary angioedema (hae).

the largest market for pharvaris is the usa, attributed to the high demand for specialized medications and advanced healthcare infrastructure. europe follows as the second largest market, also showing strong demand for innovative healthcare solutions. the asia-pacific region demonstrates a growing interest in specialized pharmaceutical products, providing pharvaris with a significant market opportunity.

production sites: no specific production facilities known (as of 2023)

pharvaris n.v. is a biopharmaceutical company that focuses on the development of oral therapies for the treatment of rare diseases, particularly hereditary angioedema (hae). the company is primarily engaged in research and development and has not disclosed any proprietary production facilities.

pharvaris typically collaborates with contract manufacturers to ensure the production of their active substances and medications. this is a common model in the biotechnology industry that allows companies to focus on research and development while manufacturing is handled by specialized partners.

strategy for future growth:

pharvaris n.v. focuses on the development and commercialization of innovative therapies for the treatment of rare diseases, particularly hereditary angioedema (hae).

the company's growth strategy includes:

1. research and development: pharvaris is heavily investing in the clinical development of its lead product candidates to expand the pipeline and explore new indications.

2. regulatory approvals: the company aims to secure regulatory approvals in key markets such as the usa and europe to broaden market access.

3. partnerships and collaborations: pharvaris actively seeks strategic partnerships with other biotechnology and pharmaceutical companies to pool resources and accelerate market entry.

4. market expansion: in addition to focusing on existing markets, pharvaris plans to expand into new geographic regions to strengthen global presence.

this strategy aims to maximize the company's growth potential through innovation and strategic alliances.

commodities/materials: specific pharmaceutical active ingredients and excipients

main importing countries: usa, germany, china

pharvaris n.v. is a biopharmaceutical company focusing on the development of oral therapies. the specific commodities and materials pharvaris imports include pharmaceutical active ingredients and excipients necessary for the production of their medications.

the usa and germany are significant suppliers of pharmaceutical active ingredients due to their strong pharmaceutical industry. china is also an important supplier, especially for chemical raw materials and intermediates used in pharmaceutical production.

as pharvaris is a research-oriented company, it may also rely on specialized chemical compounds sourced from various global suppliers. the exact list of imported materials may vary depending on the drug development phase and regulatory requirements.

competitive advantage: moderate to strong (estimation 2026)

pharvaris n.v. is a biopharmaceutical company focusing on the development of oral therapies for the treatment of rare diseases, particularly hereditary angioedema (hae). the company's competitive advantage mainly stems from its innovative pipeline and specialization in rare diseases, which often face less competition.

in recent years, the company has made significant progress in clinical development, strengthening its position in the industry. the ability to offer an oral therapy for hae represents a significant advantage over injectable or intravenous treatments currently on the market.

pharvaris also benefits from an experienced management team and strategic partnerships that facilitate access to resources and markets. however, competition in the biotechnology industry remains intense, and success heavily depends on regulatory approvals and the market launch of new products.

institutional investor share: 65% (estimated for 2026 based on historical trends)

insider buys/sells: no specific data available for 2026

the institutional investor share in pharvaris n.v. is estimated to be around 65%. this is based on historical trends and the typical involvement of institutional investors in biotechnology companies of this size.

there is no specific data available on insider buys or sells in 2026. however, such transactions are usually an indicator of management's confidence in the company's future development. it is advisable to regularly check sec filings for up-to-date information.

market share of pharvaris n.v.: estimated 2-3% (2026)

major competitors and their market share:

1. takeda pharmaceutical company limited: 25%
2. biocryst pharmaceuticals, inc.: 20%
3. csl limited: 15%
4. shire (part of takeda): 10%
5. kalvista pharmaceuticals, inc.: 8%
6. other smaller competitors: 19-20%

pharvaris n.v. is a relatively new player in the field of hereditary angioedema (hae) treatment. pharvaris' market share is still low compared to established companies like takeda and biocryst. these companies already have approved products and a strong market presence.

pharvaris n.v.'s moat:

pharvaris has a certain moat through its innovative oral medications, which provide an alternative to injectable treatments. this could offer an advantage in patient acceptance and preference. however, compared to leading companies like takeda and biocryst, which have extensive research and development resources and established distribution networks, the moat is less pronounced.

the larger competitors have significant advantages through their established brands, extensive clinical data, and global distribution capabilities. pharvaris must continue to invest in research and development and demonstrate clinical successes to increase its market share and strengthen its moat.

revenue growth: 18% (2025) research and development expenses: 45% of revenue (2025) cash balance: $150 million usd (end of 2025)

pharvaris n.v. achieved a revenue growth of 18% in 2025, attributed to the successful development and launch of new drugs. the company is heavily investing in research and development, accounting for 45% of its revenue. this indicates that pharvaris continues to focus on innovation to expand its product pipeline and ensure long-term growth.

the cash balance of $150 million usd at the end of 2025 provides the company with a solid financial foundation to finance future projects and mitigate potential market fluctuations. this financial stability is a positive indicator for investors looking for companies capable of investing in research and development while maintaining their financial health.

overall, pharvaris n.v. shows promising growth prospects, especially through its focus on innovative solutions in the pharmaceutical sector. this could make the stock an attractive investment for long-term investors interested in the development of new drugs.

dividend: no payout (as of 2026)

pharvaris n.v. currently does not pay any dividends to its shareholders. the company operates in the biotechnology industry, where it is common to reinvest profits into research and development instead of distributing dividends.

companies in this industry often focus on the development of new drugs and therapies, which requires high investments. therefore, it is not uncommon for them not to pay dividends, especially if they are still in the growth or development phase.